FINE FOODS & PHARMACEUTICALS (FF.MI) Stock Fundamental Analysis
Europe - Euronext Milan - BIT:FF - IT0005215329 - Common Stock
9.56 EUR
+0.12 (+1.27%)
Taking everything into account, FF scores 6 out of 10 in our fundamental rating. FF was compared to 19 industry peers in the Life Sciences Tools & Services industry. FF has an average financial health and profitability rating. FF is valued quite cheap, while showing a decent growth score. This is a good combination! These ratings could make FF a good candidate for value investing.
1. Profitability
1.1 Basic Checks
In the past year FF was profitable.
FF had a positive operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: FF reported negative net income in multiple years.
FF had a positive operating cash flow in 4 of the past 5 years.
1.2 Ratios
FF has a better Return On Assets (6.89%) than 89.47% of its industry peers.
FF has a better Return On Equity (13.58%) than 84.21% of its industry peers.
FF's Return On Invested Capital of 9.84% is amongst the best of the industry. FF outperforms 89.47% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for FF is below the industry average of 7.47%.
The last Return On Invested Capital (9.84%) for FF is above the 3 year average (3.16%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.89% | ||
| ROE | 13.58% | ||
| ROIC | 9.84% |
ROA(3y)-0.42%
ROA(5y)0.94%
ROE(3y)-1.24%
ROE(5y)0.96%
ROIC(3y)3.16%
ROIC(5y)3.16%
1.3 Margins
The Profit Margin of FF (5.07%) is worse than 68.42% of its industry peers.
FF has a worse Operating Margin (7.85%) than 78.95% of its industry peers.
FF's Operating Margin has improved in the last couple of years.
Looking at the Gross Margin, with a value of 34.77%, FF is in line with its industry, outperforming 47.37% of the companies in the same industry.
In the last couple of years the Gross Margin of FF has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 7.85% | ||
| PM (TTM) | 5.07% | ||
| GM | 34.77% |
OM growth 3Y24.97%
OM growth 5Y2.12%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.32%
GM growth 5Y2.27%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so FF is still creating some value.
The number of shares outstanding for FF remains at a similar level compared to 1 year ago.
Compared to 5 years ago, FF has more shares outstanding
The debt/assets ratio for FF has been reduced compared to a year ago.
2.2 Solvency
An Altman-Z score of 3.05 indicates that FF is not in any danger for bankruptcy at the moment.
FF has a Altman-Z score of 3.05. This is in the better half of the industry: FF outperforms 63.16% of its industry peers.
A Debt/Equity ratio of 0.44 indicates that FF is not too dependend on debt financing.
The Debt to Equity ratio of FF (0.44) is better than 78.95% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.44 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 3.05 |
ROIC/WACC1.16
WACC8.47%
2.3 Liquidity
FF has a Current Ratio of 1.67. This is a normal value and indicates that FF is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.67, FF belongs to the top of the industry, outperforming 89.47% of the companies in the same industry.
FF has a Quick Ratio of 1.07. This is a normal value and indicates that FF is financially healthy and should not expect problems in meeting its short term obligations.
With a Quick ratio value of 1.07, FF perfoms like the industry average, outperforming 47.37% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.67 | ||
| Quick Ratio | 1.07 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 147.03% over the past year.
FF shows a small growth in Revenue. In the last year, the Revenue has grown by 1.78%.
Measured over the past years, FF shows a quite strong growth in Revenue. The Revenue has been growing by 8.83% on average per year.
EPS 1Y (TTM)147.03%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%3.62%
Revenue 1Y (TTM)1.78%
Revenue growth 3Y7.75%
Revenue growth 5Y8.83%
Sales Q2Q%12.18%
3.2 Future
FF is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 26.88% yearly.
FF is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 12.10% yearly.
EPS Next Y35.61%
EPS Next 2Y31.63%
EPS Next 3Y27.28%
EPS Next 5Y26.88%
Revenue Next Year6.76%
Revenue Next 2Y10.32%
Revenue Next 3Y10.11%
Revenue Next 5Y12.1%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 10.74, the valuation of FF can be described as very reasonable.
94.74% of the companies in the same industry are more expensive than FF, based on the Price/Earnings ratio.
The average S&P500 Price/Earnings ratio is at 26.15. FF is valued rather cheaply when compared to this.
Based on the Price/Forward Earnings ratio of 14.62, the valuation of FF can be described as correct.
Based on the Price/Forward Earnings ratio, FF is valued cheaply inside the industry as 94.74% of the companies are valued more expensively.
Compared to an average S&P500 Price/Forward Earnings ratio of 36.12, FF is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.74 | ||
| Fwd PE | 14.62 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, FF is valued cheaper than 100.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 5.82 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of FF may justify a higher PE ratio.
FF's earnings are expected to grow with 27.28% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.3
PEG (5Y)N/A
EPS Next 2Y31.63%
EPS Next 3Y27.28%
5. Dividend
5.1 Amount
FF has a Yearly Dividend Yield of 1.55%.
Compared to an average industry Dividend Yield of 0.73, FF pays a better dividend. On top of this FF pays more dividend than 94.74% of the companies listed in the same industry.
FF's Dividend Yield is slightly below the S&P500 average, which is at 2.41.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.55% |
5.2 History
The dividend of FF has a limited annual growth rate of 4.24%.
Dividend Growth(5Y)4.24%
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
FF pays out 18.40% of its income as dividend. This is a sustainable payout ratio.
FF's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP18.4%
EPS Next 2Y31.63%
EPS Next 3Y27.28%
BIT:FF (11/26/2025, 5:23:32 PM)
9.56
+0.12 (+1.27%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners12.42%
Inst Owner ChangeN/A
Ins Owners53.17%
Ins Owner ChangeN/A
Market Cap210.89M
Revenue(TTM)373.66M
Net Income(TTM)18.62M
Analysts85.45
Price Target12.51 (30.86%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.55% |
Yearly Dividend0.12
Dividend Growth(5Y)4.24%
DP18.4%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)1.66%
PT rev (3m)1.66%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0.67%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.74 | ||
| Fwd PE | 14.62 | ||
| P/S | 0.57 | ||
| P/FCF | N/A | ||
| P/OCF | 5.72 | ||
| P/B | 1.54 | ||
| P/tB | 1.7 | ||
| EV/EBITDA | 5.82 |
EPS(TTM)0.89
EY9.31%
EPS(NY)0.65
Fwd EY6.84%
FCF(TTM)-0.21
FCFYN/A
OCF(TTM)1.67
OCFY17.5%
SpS16.64
BVpS6.22
TBVpS5.62
PEG (NY)0.3
PEG (5Y)N/A
Graham Number11.16
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.89% | ||
| ROE | 13.58% | ||
| ROCE | 14.28% | ||
| ROIC | 9.84% | ||
| ROICexc | 11.04% | ||
| ROICexgc | 11.92% | ||
| OM | 7.85% | ||
| PM (TTM) | 5.07% | ||
| GM | 34.77% | ||
| FCFM | N/A |
ROA(3y)-0.42%
ROA(5y)0.94%
ROE(3y)-1.24%
ROE(5y)0.96%
ROIC(3y)3.16%
ROIC(5y)3.16%
ROICexc(3y)3.64%
ROICexc(5y)4.57%
ROICexgc(3y)4.02%
ROICexgc(5y)5.02%
ROCE(3y)4.59%
ROCE(5y)4.62%
ROICexgc growth 3Y13.05%
ROICexgc growth 5Y-1.19%
ROICexc growth 3Y17.44%
ROICexc growth 5Y-2.63%
OM growth 3Y24.97%
OM growth 5Y2.12%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.32%
GM growth 5Y2.27%
F-Score7
Asset Turnover1.36
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.44 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 1.35 | ||
| Cap/Depr | 262.56% | ||
| Cap/Sales | 11.33% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 82.61% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.67 | ||
| Quick Ratio | 1.07 | ||
| Altman-Z | 3.05 |
F-Score7
WACC8.47%
ROIC/WACC1.16
Cap/Depr(3y)145.26%
Cap/Depr(5y)138.08%
Cap/Sales(3y)9.82%
Cap/Sales(5y)9.37%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)147.03%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%3.62%
EPS Next Y35.61%
EPS Next 2Y31.63%
EPS Next 3Y27.28%
EPS Next 5Y26.88%
Revenue 1Y (TTM)1.78%
Revenue growth 3Y7.75%
Revenue growth 5Y8.83%
Sales Q2Q%12.18%
Revenue Next Year6.76%
Revenue Next 2Y10.32%
Revenue Next 3Y10.11%
Revenue Next 5Y12.1%
EBIT growth 1Y70.93%
EBIT growth 3Y34.65%
EBIT growth 5Y11.14%
EBIT Next Year132.69%
EBIT Next 3Y46.53%
EBIT Next 5Y31.96%
FCF growth 1Y57.35%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y568.5%
OCF growth 3YN/A
OCF growth 5Y19.07%
FINE FOODS & PHARMACEUTICALS / FF.MI FAQ
What is the fundamental rating for FF stock?
ChartMill assigns a fundamental rating of 6 / 10 to FF.MI.
What is the valuation status of FINE FOODS & PHARMACEUTICALS (FF.MI) stock?
ChartMill assigns a valuation rating of 7 / 10 to FINE FOODS & PHARMACEUTICALS (FF.MI). This can be considered as Undervalued.
Can you provide the profitability details for FINE FOODS & PHARMACEUTICALS?
FINE FOODS & PHARMACEUTICALS (FF.MI) has a profitability rating of 6 / 10.
What are the PE and PB ratios of FINE FOODS & PHARMACEUTICALS (FF.MI) stock?
The Price/Earnings (PE) ratio for FINE FOODS & PHARMACEUTICALS (FF.MI) is 10.74 and the Price/Book (PB) ratio is 1.54.
What is the expected EPS growth for FINE FOODS & PHARMACEUTICALS (FF.MI) stock?
The Earnings per Share (EPS) of FINE FOODS & PHARMACEUTICALS (FF.MI) is expected to grow by 35.61% in the next year.